A Phase 4 interventional study of EMLA and Lidocaine in Leukemia-Lymphoma, sponsored by CAMC Health System. Completed at 1 site in United States. Open to participants aged 3 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by CAMC Health System · Phase 4, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A common procedure in children with cancer is the spinal tap, or lumbar puncture (LP), in which a needle is inserted into the spinal canal. In this population, LPs are most commonly performed to collect cerebrospinal fluid (CSF, the liquid surrounding the brain and spinal cord) for diagnostic testing, and to inject medications including chemotherapy. Local analgesic (pain control medicine) during pediatric LP procedures is underutilized and not standardized. The first local analgesic routinely used for LP procedures was lidocaine injection. The discovery of the topical EMLA (lidocaine 2.5%/prilocaine 2.5%) cream, approved by the FDA for local skin use in pediatric patients, has provided an additional option for local LP analgesia. A comparison between topical EMLA vs lidocaine injection for LP pain control in the pediatric population has not been performed. Pediatric oncology patients often require serial LPs for diagnostics purposes and/or chemotherapy delivery. Due to a lack of standardization of LP analgesia in this population, the investigators have designed a prospective, single-blind, randomized control crossover trial to examine EMLA vs. lidocaine injection in reducing pain associated with LP in children being treated for leukemia or lymphoma.
CAMC Health System is the lead sponsor of 47 studies on the registry; 3 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 2 (40%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The patient will receive 5 grams EMLA cream at the site of the lumbar puncture at least 60 minutes prior to procedure. The site of EMLA application will be covered with Tegaderm dressing.
Drug: EMLA
The patient will receive sham-EMLA cream (a fragrance-free hypoallergenic moisturizer cream) will be applied at least 60 minutes per standard protocol with Tegaderm dressing.- Following conscious sedation, the patient will receive lidocaine 1% injection (\~1-2ml) at the appropriate site 30-60 seconds prior to LP needle insertion.
Drug: Lidocaine
Drug pages: LidocaineStudies of LidocaineLidocaine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · PrilocaineStudies of PrilocainePrilocaine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
EMLA cream (lidocaine 2.5% and prilocaine 2.5%)
lidocaine 1%
Post Lumbar Puncture Pain Score at 30-60 Minutes
Wong-Baker Faces Pain Rating Scale assessed 30-60 minutes following lumbar puncture. Wong-Baker Faces Pain Rating Scale shows a series of six faces ranging from a happy face at 0, or "no hurt", to a crying face at 10, which represents "hurts like the worst pain imaginable". Based on the faces and written descriptions, the patient chooses the face that best describes their level of pain, with higher the number, greater the pain.
Time frame: 30-60 minutes after lumbar puncture
Post Lumbar Puncture Pain Score at 24 Hours
Wong-Baker Faces Pain Rating Scale assessed 30-60 minutes following lumbar puncture. Wong-Baker Faces Pain Rating Scale shows a series of six faces ranging from a happy face at 0, or "no hurt", to a crying face at 10, which represents "hurts like the worst pain imaginable". Based on the faces and written descriptions, the patient chooses the face that best describes their level of pain, with higher the number, greater the pain.
Time frame: 24 hours after lumbar puncture
Post Lumbar Puncture PRN Pain Medication Usage
Use of PRN or "as needed" pain medicine by the patient was determined. Patients with parent/guardian assistance were asked to record the "as needed" pain control medication, acetaminophen. the patient used within the 24 hours after lumber puncture. Counts of patients using acetaminophen in the 24 hours following lumber puncture are reported.
Time frame: 24 hours following lumbar puncture
10 patients were screen and enrolled in the study
| Milestone | EMLA for First Lumbar Puncture, Lidocaine Injection for Second Lumbar Puncture | Lidocaine Injection for First Lumbar Puncture, EMLA for Second Lumbar Puncture |
|---|---|---|
| Started | 5 | 5 |
| Completed | 5 | 5 |
| Not completed | 0 | 0 |
Wong-Baker Faces Pain Rating Scale assessed 30-60 minutes following lumbar puncture. Wong-Baker Faces Pain Rating Scale shows a series of six faces ranging from a happy face at 0, or "no hurt", to a crying face at 10, which represents "hurts like the worst pain imaginable". Based on the faces and written descriptions, the patient chooses the face that best describes their level of pain, with higher the number, greater the pain.
| score on a scale | EMLA | Lidocaine Injection |
|---|---|---|
| Post Lumbar Puncture Pain Score at 30-60 Minutes | 0 (0 to 0) | 0 (0 to 0) |
Use of PRN or "as needed" pain medicine by the patient was determined. Patients with parent/guardian assistance were asked to record the "as needed" pain control medication, acetaminophen. the patient used within the 24 hours after lumber puncture. Counts of patients using acetaminophen in the 24 hours following lumber puncture are reported.
| Participants | EMLA | Lidocaine |
|---|---|---|
| Post Lumbar Puncture PRN Pain Medication Usage | 1 | 2 |
Wong-Baker Faces Pain Rating Scale assessed 30-60 minutes following lumbar puncture. Wong-Baker Faces Pain Rating Scale shows a series of six faces ranging from a happy face at 0, or "no hurt", to a crying face at 10, which represents "hurts like the worst pain imaginable". Based on the faces and written descriptions, the patient chooses the face that best describes their level of pain, with higher the number, greater the pain.
| score on a scale | EMLA | Lidocaine Injection |
|---|---|---|
| Post Lumbar Puncture Pain Score at 24 Hours | 0 (0 to 8) | 0 (0 to 8) |
Collected over 7 days for each intervention. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| EMLA | 0/10 (0%) | 0/10 (0%) | 0/10 (0%) |
| Lidocaine Injection | 0/10 (0%) | 0/10 (0%) | 0/10 (0%) |
| Age, Continuous(years) | EMLA for First Lumbar Puncture, Lidocaine Injection for Second Lumbar Puncture | Lidocaine Injection for First Lumbar Puncture, EMLA for Second Lumbar Puncture | Total |
|---|---|---|---|
| Median | 5 (3.5 to 14) | 6 (4 to 11) | 5.5 (4 to 11) |
| Sex: Female, Male(Participants) | EMLA for First Lumbar Puncture, Lidocaine Injection for Second Lumbar Puncture | Lidocaine Injection for First Lumbar Puncture, EMLA for Second Lumbar Puncture | Total |
|---|---|---|---|
| Female | 1 | 3 | 4 |
| Male | 4 | 2 | 6 |
| Race (NIH/OMB)(Participants) | EMLA for First Lumbar Puncture, Lidocaine Injection for Second Lumbar Puncture | Lidocaine Injection for First Lumbar Puncture, EMLA for Second Lumbar Puncture | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 5 | 5 | 10 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | EMLA for First Lumbar Puncture, Lidocaine Injection for Second Lumbar Puncture | Lidocaine Injection for First Lumbar Puncture, EMLA for Second Lumbar Puncture | Total |
|---|---|---|---|
| United States | 5 | 5 | 10 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2019 to primary completion in Jul 2021, 24 months.
Results were first posted in Mar 2023, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Lidocaine · Prilocaine
CAMC Health System